Cough: Clinical Trials

8 trials for Cough, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 terminated. 8 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 28Terminated 8
Phase 11Terminated 1

Follow Cough: new trials by email Literature Review of Cough trials Research Report on Cough

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.
RV521, Placebo - Respiratory Syncytial Virus (RSV), Lower Resp Tract Infection
Phase 2TerminatedPfizer512019-11-132024-10-23
A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
BLU-5937, Placebo - Chronic Refractory Cough
Phase 2TerminatedBellus Health Inc. - a GSK company682019-07-102021-08-03
A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF
RVT-1601, Placebo - Persistent Cough in IPF, Chronic Cough
Phase 2TerminatedRespivant Sciences GmbH1082019-03-292020-06-11
A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough
GSK2798745, Placebo - Cough
Phase 1 / Phase 2TerminatedGlaxoSmithKline172018-04-052019-10-02
Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients
QCC374 - Pulmonary Arterial Hypertension
Phase 2TerminatedNovartis Pharmaceuticals52018-02-012021-01-05
Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
QCC374, Placebo Matching - Pulmonary Arterial Hypertension
Phase 2TerminatedNovartis Pharmaceuticals82017-09-192021-01-05
Phase II Open-Label Pilot Study of V3381 in Chronic Cough
Indantadol - Cough
Phase 2TerminatedVernalis (R&D) Ltd122009-10-012011-07-25
Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis
interferon-alpha lozenges, placebo lozenges - Pulmonary Disease, Chronic Obstructive, Pulmonary Fibrosis
Phase 2TerminatedAinos, Inc. (f/k/a Amarillo Biosciences Inc.12008-06-012012-04-24

Narrower conditions

Chronic Cough (5)  ·  Dizziness (2)  ·  Dyspnea (2)  ·  Hypertension, Pulmonary (2)  ·  Pulmonary Arterial Hypertension (2)  ·  Syncope (2)  ·  Pulmonary Disease, Chronic Obstructive (1)  ·  Pulmonary Fibrosis (1)  ·  Respiratory Sounds (1)  ·  Rhinitis (1)

Broader conditions

Pathological Conditions, Signs and Symptoms (8)  ·  Respiration Disorders (8)  ·  Respiratory Tract Diseases (8)  ·  Signs and Symptoms (8)  ·  Signs and Symptoms, Respiratory (8)  ·  Lung Diseases (3)  ·  Cardiovascular Diseases (2)  ·  Consciousness Disorders (2)  ·  Hypertension (2)  ·  Nervous System Diseases (2)  ·  Neurobehavioral Manifestations (2)  ·  Neurologic Manifestations (2)  ·  Sensation Disorders (2)  ·  Unconsciousness (2)  ·  Vascular Diseases (2)

Interventions

BLU-5937 (1)  ·  GSK2798745 (1)  ·  Interferon-alpha (1)  ·  indantadol (1)  ·  sisunatovir (1)

Sponsors

Novartis Pharmaceuticals (2)  ·  Ainos, Inc. (f/k/a Amarillo Biosciences Inc. (1)  ·  Bellus Health Inc. - a GSK company (1)  ·  GlaxoSmithKline (1)  ·  Pfizer (1)  ·  Respivant Sciences GmbH (1)  ·  Vernalis (R&D) Ltd (1)

Countries

United Kingdom (7)  ·  United States (5)  ·  Germany (3)  ·  Canada (2)  ·  New Zealand (2)  ·  South Korea (2)  ·  Argentina (1)  ·  Australia (1)  ·  Belgium (1)  ·  Chile (1)  ·  Costa Rica (1)  ·  Czechia (1)  ·  Hungary (1)  ·  Israel (1)  ·  Italy (1)

Top investigators

Ahmet Tutuncu, MD, PhD (1)  ·  Ashley Woodcock, Prof. (1)  ·  Jacky Smith, MD, Ph.D. (1)  ·  Lorenz O Lutherer, MD, PhD (1)

NIH funding

2016 (1), 2017 (1), 2019 (1)